210 related articles for article (PubMed ID: 23087817)
1. In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids.
Galili U; Albertini MR; Sondel PM; Wigglesworth K; Sullivan M; Whalen GF
Cancers (Basel); 2010; 2(2):773-93. PubMed ID: 23087817
[TBL] [Abstract][Full Text] [Related]
2. Conversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction.
Galili U
Clin Dev Immunol; 2011; 2011():134020. PubMed ID: 22162709
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
Galili U; Wigglesworth K; Abdel-Motal UM
J Immunol; 2007 Apr; 178(7):4676-87. PubMed ID: 17372027
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.
Abdel-Motal UM; Wigglesworth K; Galili U
Cancer Immunol Immunother; 2009 Oct; 58(10):1545-56. PubMed ID: 19184002
[TBL] [Abstract][Full Text] [Related]
5. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
Galili U
Immunol Cell Biol; 2005 Dec; 83(6):674-86. PubMed ID: 16266320
[TBL] [Abstract][Full Text] [Related]
6. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
7. Autologous tumor vaccines processed to express alpha-gal epitopes: a practical approach to immunotherapy in cancer.
Galili U
Cancer Immunol Immunother; 2004 Nov; 53(11):935-45. PubMed ID: 15205919
[TBL] [Abstract][Full Text] [Related]
8. Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
Galili U
Med Res Arch; 2021 Jul; 9(7):. PubMed ID: 34853815
[TBL] [Abstract][Full Text] [Related]
9. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
Deriy L; Ogawa H; Gao GP; Galili U
Cancer Gene Ther; 2005 Jun; 12(6):528-39. PubMed ID: 15818383
[TBL] [Abstract][Full Text] [Related]
10. Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Taniyama K; Kamiike W; Mori M; Doki Y
Cancer Sci; 2013 Mar; 104(3):282-90. PubMed ID: 23240661
[TBL] [Abstract][Full Text] [Related]
11. Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine.
Galili U; Chen ZC; DeGeest K
Gynecol Oncol; 2003 Jul; 90(1):100-8. PubMed ID: 12821349
[TBL] [Abstract][Full Text] [Related]
12. AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.
Shaw SM; Middleton J; Wigglesworth K; Charlemagne A; Schulz O; Glossop MS; Whalen GF; Old R; Westby M; Pickford C; Tabakman R; Carmi-Levy I; Vainstein A; Sorani E; Zur AA; Kristian SA
Cancer Cell Int; 2019; 19():346. PubMed ID: 31889898
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.
Albertini MR; Ranheim EA; Zuleger CL; Sondel PM; Hank JA; Bridges A; Newton MA; McFarland T; Collins J; Clements E; Henry MB; Neuman HB; Weber S; Whalen G; Galili U
Cancer Immunol Immunother; 2016 Aug; 65(8):897-907. PubMed ID: 27207605
[TBL] [Abstract][Full Text] [Related]
14. Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies.
Galili U
Front Mol Biosci; 2021; 8():746883. PubMed ID: 34805272
[TBL] [Abstract][Full Text] [Related]
15. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
[TBL] [Abstract][Full Text] [Related]
17. In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids.
Galili U
Oncoimmunology; 2013 Jan; 2(1):e22449. PubMed ID: 23483105
[TBL] [Abstract][Full Text] [Related]
18. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits.
Galili U
Immunology; 2013 Sep; 140(1):1-11. PubMed ID: 23578170
[TBL] [Abstract][Full Text] [Related]
19. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
[TBL] [Abstract][Full Text] [Related]
20. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
